Pathophysiology and Treatment of Lipid Abnormalities in Cerebrotendinous Xanthomatosis: An Integrative Review
- PMID: 37508912
- PMCID: PMC10377253
- DOI: 10.3390/brainsci13070979
Pathophysiology and Treatment of Lipid Abnormalities in Cerebrotendinous Xanthomatosis: An Integrative Review
Abstract
Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive disorder caused by pathogenic variants in CYP27A1, leading to a deficiency in sterol 27-hydroxylase. This defect results in the accumulation of cholestanol and bile alcohols in various tissues, including the brain, tendons and peripheral nerves. We conducted this review to evaluate lipid profile abnormalities in patients with CTX. A search was conducted in PubMed, Embase and the Virtual Health Library in January 2023 to evaluate studies reporting the lipid profiles of CTX patients, including the levels of cholestanol, cholesterol and other lipids. Elevated levels of cholestanol were consistently observed. Most patients presented normal or low serum cholesterol levels. A decrease in chenodeoxycholic acid (CDCA) leads to increased synthesis of cholesterol metabolites, such as bile alcohols 23S-pentol and 25-tetrol 3-glucuronide, which may serve as surrogate follow-up markers in patients with CTX. Lipid abnormalities in CTX have clinical implications. Cholestanol deposition in tissues contributes to clinical manifestations, including neurological symptoms and tendon xanthomas. Dyslipidemia and abnormal cholesterol metabolism may also contribute to the increased risk of atherosclerosis and cardiovascular complications observed in some CTX patients.
Keywords: cerebrotendinous xanthomatosis; chenodeoxycholic acid; cholestanol; cholesterol; lipid.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Efficacy, safety, and tolerability of chenodeoxycholic acid (CDCA) in adult patients with cerebrotendinous xanthomatosis (RESTORE): A randomized withdrawal, double-blind, placebo-controlled, crossover phase-3 study.Genet Med. 2025 Jul;27(7):101449. doi: 10.1016/j.gim.2025.101449. Epub 2025 Apr 25. Genet Med. 2025. PMID: 40297984 Clinical Trial.
-
Cerebrotendinous Xanthomatosis.2003 Jul 16 [updated 2024 Nov 14]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2003 Jul 16 [updated 2024 Nov 14]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301583 Free Books & Documents. Review.
-
Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.J Atheroscler Thromb. 2021 Sep 1;28(9):905-925. doi: 10.5551/jat.RV17055. Epub 2021 May 8. J Atheroscler Thromb. 2021. PMID: 33967188 Free PMC article.
-
A case of Cerebrotendinous Xanthomatosis with spinal cord involvement and without tendon xanthomas: identification of a new mutation of the CYP27A1 gene.Acta Neurol Belg. 2021 Apr;121(2):561-566. doi: 10.1007/s13760-019-01267-4. Epub 2019 Dec 24. Acta Neurol Belg. 2021. PMID: 31875301
-
Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management.Orphanet J Rare Dis. 2014 Nov 26;9:179. doi: 10.1186/s13023-014-0179-4. Orphanet J Rare Dis. 2014. PMID: 25424010 Free PMC article. Review.
Cited by
-
Cholic acid as a treatment for cerebrotendinous xanthomatosis: a comprehensive review of safety and efficacy.Orphanet J Rare Dis. 2025 Jul 29;20(1):387. doi: 10.1186/s13023-025-03889-9. Orphanet J Rare Dis. 2025. PMID: 40731019 Free PMC article. Review.
-
Surgical Treatment of Multiple Large Tuberous and Tendinous Xanthoma Secondary to Familial Hypercholesterolaemia: A Case Report.Clin Cosmet Investig Dermatol. 2024 Apr 29;17:961-966. doi: 10.2147/CCID.S445163. eCollection 2024. Clin Cosmet Investig Dermatol. 2024. PMID: 38707607 Free PMC article.
-
Frontier and hotspot evolution in cerebrotendinous xanthomatosis: a bibliometric analysis from 1993 to 2023.Front Neurol. 2024 Jul 26;15:1371375. doi: 10.3389/fneur.2024.1371375. eCollection 2024. Front Neurol. 2024. PMID: 39131052 Free PMC article.
-
Editorial for Brain Sciences Special Issue: "Neurogenetic Disorders across Human Life: From Infancy to Adulthood".Brain Sci. 2024 Jan 23;14(2):111. doi: 10.3390/brainsci14020111. Brain Sci. 2024. PMID: 38391686 Free PMC article.
-
A diagnostic approach to neurocutaneous syndromes.Arq Neuropsiquiatr. 2025 Jul;83(7):1-14. doi: 10.1055/s-0045-1809664. Epub 2025 Jun 25. Arq Neuropsiquiatr. 2025. PMID: 40562378 Free PMC article. Review.
References
-
- Höflinger P., Hauser S., Yutuc E., Hengel H., Griffiths L., Radelfahr F., Howell O.W., Wang Y., Connor S.L., Duell P.B., et al. Metabolic profiling in serum, cerebrospinal fluid, and brain of patients with cerebrotendinous xanthomatosis. J. Lipid Res. 2021;62:100078. doi: 10.1016/j.jlr.2021.100078. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources